FDA approves three updated 2026–27 COVID-19 vaccines from Pfizer/BioNTech and Moderna

FDA clears three updated 2026–27 COVID-19 vaccines from Pfizer/BioNTech and Moderna

The U.S. Food and Drug Administration has approved supplemental biologics license applications for three updated 2026–27 COVID-19 vaccines, according to news releases from Pfizer and BioNTech and from Moderna dated Aug. 27. Becker’s Hospital Review reported the approvals in a brief item summarizing the announcements.

What the announcement says

Company news releases state that the FDA granted approvals for supplemental biologics license applications covering three updated vaccine formulations intended for the 2026–27 season. The source identifies the manufacturers—Pfizer and BioNTech and Moderna—and the date of the company releases (Aug. 27).

The Becker’s Hospital Review post carried the headline presenting the information in a "5 things to know" format, but the text provided to this report did not include the five specific points, names of the updated vaccines, regulatory details, safety or efficacy data, or indications for use.

What was not reported in the source

The source material is limited to the companies’ Aug. 27 news releases and does not supply several types of information clinicians and health systems typically seek after vaccine approvals. Specifically, the following items were not reported:

• Exact product names or formulation details for the three updated vaccines.
• The FDA’s summary basis for approval, including any trial results, immunogenicity data or assessment of safety and effectiveness.
• Age groups or patient populations for which the supplements were approved.
• Dosing schedules, booster recommendations or interchangeability guidance with prior vaccines.
• Distribution, availability timelines, or manufacturing and supply details.
• Any statements from the FDA, federal health agencies, or independent advisory committees.

Readers looking for those details will need to consult the full company releases or the FDA’s official communications, which typically include labeling updates and clinical evidence summaries when available.

Why this matters for providers and health systems

Approvals of updated COVID-19 vaccines for new seasons can affect clinical recommendations, procurement, and vaccination campaigns. When manufacturers update vaccine formulations, hospital systems and outpatient practices often look for:

• Official FDA labeling and authorization language to confirm approved indications and age ranges.
• Public health guidance from federal or state agencies on recommended populations and timing for vaccination.
• Supply and ordering information to plan inventory and clinic schedules.

Because the source article did not include these operational details, institutions should follow up with the FDA and the companies’ full press materials before making policy or ordering decisions.

Context and next steps (as supported by the source)

The Becker’s Hospital Review item is a short news alert summarizing that approvals occurred; it did not provide broader context about circulating variants, seasonality, or preventive strategies. The only confirmed facts from the source are the FDA’s approval action for supplemental biologics license applications and the involvement of Pfizer/BioNTech and Moderna with three updated 2026–27 formulations.

For stakeholders who need to act on this news, the next steps are clear even if the source lacked operational detail:

• Review the full Aug. 27 news releases from Pfizer and BioNTech and from Moderna for any additional specifics included by the companies.
• Check the FDA website for official approval letters, labeling changes and summaries of the evidence used to support the supplemental approvals.
• Watch for guidance from the Centers for Disease Control and Prevention and state health departments about clinical recommendations and vaccine rollout plans.

Where to find full details

This article is based solely on the Becker’s Hospital Review item referencing company news releases. It did not reproduce or quote the companies’ full statements. To obtain comprehensive, source-level information, consult:

• The full Aug. 27 news releases issued by Pfizer and BioNTech and by Moderna.
• The FDA’s public communications and approval documents related to supplemental biologics license applications.
• Advisories from public health agencies that interpret regulatory actions for clinical use.

Bottom line

The FDA has approved supplemental biologics license applications for three updated 2026–27 COVID-19 vaccines from Pfizer and BioNTech and Moderna, according to Aug. 27 company news releases reported by Becker’s Hospital Review. The short source item did not provide product names, data, labeling specifics, recommended use, or implementation guidance. Readers should consult the companies’ full releases and the FDA for complete information.